Q-omics provides the consensus-scored RNF121 profile across patient tissues and cancer cell-line models. RNF121 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF121 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RNF121 RNA expression shows 20,148 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where RNF121 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF121 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF121 survival associations across molecular data types. RNF121 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF121 RNA expression–survival associations across cancer types. High RNF121 expression shows unfavorable associations in ACC, PAAD, UVM, LUAD and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF121 RNA expression.
This table summarizes RNF121 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF121. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF121 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, LUSC, LUAD and STAD. The HNSC box plot shows higher RNF121 RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with RNF121 in patient tissues and cancer cell lines. In patient samples, RNF121 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF121 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
